TheraRadar
← Back
Data updated: Jun 28, 2026

BEIJING

Generics
OncologyInfectious DiseaseImmunology Execution: Fair

BEIJING is a generic drug manufacturer focused on Oncology, Infectious Disease, Immunology.

2021
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

BEIJING at a Glance

  • Growing R&D activity with 39 trials in last 2 years
  • Fast trial execution (20 months median completion)

BEIJING's Key Drugs

BEIJING's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

BEIJING's Recent FDA Approvals

New NDA/BLA approvals for BEIJING over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BEIJING's Therapeutic Areas

BEIJING's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 52%
0 drugs Phase 3: 12 Phase 2: 25 Phase 1: 78
Infectious Disease 14%
0 drugs Phase 3: 7 Phase 2: 6 Phase 1: 7
Immunology 12%
0 drugs Phase 3: 3 Phase 2: 7 Phase 1: 15
Gastroenterology 12%
0 drugs Phase 3: 5 Phase 2: 7 Phase 1: 6
Cardiovascular 11%
1 drugs Phase 3: 5 Phase 2: 3 Phase 1: 4

BEIJING Pipeline Snapshot

BEIJING has 190 active clinical programs from ClinicalTrials.gov — 32 Phase 3, 48 Phase 2 and 110 Phase 1.

32
Phase 3
48
Phase 2
110
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 13/37 completed
  • • Speed: 20 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges